TransMedics (TMDX) Q3 2026 earnings review
TransMedics organ sales speed up, but research costs cut profit
TransMedics, which makes warm-perfusion machines and flies donor organs to transplant hospitals, grew through its usual summer slowdown while heavy research spending pushed profit down. Sales from businesses it owned a year ago rose 35% to $194 million, lifting total revenue to $203 million. Chief executive Waleed Hassanein raised the full-year outlook and won US regulatory clearance in October to start the delayed heart and lung clinical trials, though by our math the updated plan points to underlying growth of about 23% in the fourth quarter.
| Sales from businesses owned a year ago | $193.6M +35% from a year ago |
|---|---|
| Total revenue (including PAD Aviation) | $203.0M +41% from a year ago |
| Profit per share, excluding one-offs | $0.51 -24% from a year ago |
| Full-year underlying revenue outlook | Raised $8M middle of the range: 25% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because the two biggest threats to top-line growth — slowing transplant volume and stalled trial approvals — both moved in the company's favor. Disposable product sales sped up and the October FDA clearances let heart and lung trials enroll patients using the company's own cold-storage cooler as the comparison group. The bad news: research spending nearly doubled and interest costs from the new headquarters lease more than doubled, cutting profit per share excluding one-offs by 24%.
The question now is whether revenue from the newly cleared heart, lung and European programs will arrive fast enough in 2027 to lift operating margins out of the low teens. Bulls see the October trial approvals and Italian flight contract unlocking a multi-year volume wave, while skeptics see clinical trial bills, kidney development and $861 million of debt and lease obligations eating up the top-line gains. Management's first 2027 margin outlook on the fourth-quarter call will settle it.
🐂 Bull Case
Transplant Volume Grew Through the Seasonal Dip
TransMedics makes the Organ Care System (OCS), a portable warm-blood machine that keeps donor hearts, lungs and livers alive outside the body, and runs the National OCS Program (NOP) to retrieve and fly those organs to hospitals. Third-quarter transplant volume normally drops in the summer, shrinking sales from the second quarter. “The third quarter of 2026 was the strongest in TransMedics’ history, with record revenue and record case volume,” chief executive Waleed Hassanein said.
- Sales from businesses owned a year ago: $193.6 million, up 34.6% from a year ago and up 1.9% from the second quarter by our math
- Product revenue from perfusion disposables: $113.4 million, up 29.4% from a year ago after growing 15.7% in the second quarter
- Full-year revenue outlook excluding PAD Aviation: raised by $8 million at the middle of the range to $750–760 million
The acceleration in disposable product sales matters because each transplant case uses one disposable module, so product revenue tracks organ volume without distortion from aviation fuel prices. Growing sequentially through the summer slowdown shows liver and heart adoption re-accelerated before the new clinical trials began contributing.
What to watch: fourth-quarter underlying revenue against the $197.5 million implied by the middle of the full-year outlook. Beating that figure would show the third-quarter surge came from lasting hospital adoption rather than timing.
FDA Cleared Heart and Lung Trials
For more than a year, regulatory delays held back two major clinical trials: ENHANCE Heart and DENOVO Lung, which test next-generation perfusion systems to expand how many donor hearts and lungs hospitals can use. Enrollment had stalled because rival makers of cold-storage coolers refused to let their devices serve as the comparison group.
In October, the US Food and Drug Administration approved both trial applications, including the company's own Controlled Hypothermic Organ Preservation System (CHOPS), a cold-storage device, as the control arm. That gives the medical device group “two shots on goal in each through OCS and CHOPS”, Hassanein said. The company also finished enrolling Part A of the heart trial in September and won approval to enroll 90 more patients under a continued access protocol.
Clearing the regulatory bottleneck removes the main obstacle to 2027 heart and lung growth, because the company no longer relies on a competitor's cooler to enroll patients. One quarter of approvals eases the timeline concern, though hospital review boards still have to sign off before patient enrollment ramps up.
What to watch: heart and lung revenue in the first quarter of 2027. A step-up in growth there will confirm that hospital centers converted the October FDA clearances into billable trial procedures.
Own Planes Lifted Transport Margins
TransMedics runs its own fleet of jets to fly donor organs, charging hospitals under service revenue. Critics argued that service sales grew faster than product sales only because the company passed through higher fuel fees or billed for cancelled flights.
Service revenue from businesses owned a year ago rose 42.8% to $80.2 million. Even after adding lower-margin charter flights from newly acquired PAD Aviation, total service gross margin reached 32.2% by our math, up from 27.8% a year ago. The transplant group credited “reduced supplemental lift utilization, lower ground transportation cost per mission, and improved leverage of fixed operating costs as volume increased”.
A 4.4-percentage-point jump in service gross margin refutes the idea that zero-margin fuel surcharges drove the growth, because flying more missions on company-owned jets rather than expensive third-party charters lowered the unit cost per trip.
What to watch: service gross margin in the fourth quarter, when PAD Aviation contributes a full period of European transplant flights. Holding service gross margin above 32% will show that aircraft utilization gains outweigh the lower margin of European charter operations.
European Aviation Deal Started in Italy
On July 1, TransMedics invested in PAD Aviation, a German private jet operator, to build a dedicated European organ transport network. Investors had no numbers on what the aviation business generates or when delayed Italian hospital contracts would begin.
The company disclosed that PAD Aviation brought in $9.4 million of charter service revenue this quarter and will add about $14 million for the full year. In October, the Andover-based group won its first European transplant logistics tender in Italy and began flying missions there, with plans to launch its transplant program in Italy, the Netherlands and Belgium in 2027.
What to watch: the implied $4.6 million of fourth-quarter PAD Aviation revenue and any 2027 European revenue target on the next call. Winning additional regional tenders in Italy will determine whether Europe covers the fixed cost of the German aviation fleet.
🐻 Bear Case
Research Spending Cut Operating Margin
Hassanein highlighted record revenue and said the OCS Kidney program — a machine to preserve donor kidneys — remains on track for “first-in-human clinical experience in the second half of 2027”. Funding kidney development, next-generation heart and lung trials, and European aviation simultaneously has broken the link between top-line growth and profit.
- Research, development and clinical trials: $29.2 million, up 91.2% from a year ago, rising 3.8 percentage points of revenue to 14.4%
- Selling, general and administrative expense: $61.3 million, up 33.3%, falling 1.8 percentage points of revenue to 30.2%
- Operating margin excluding one-offs: 14.2%, down 2.2 percentage points from 16.4% a year ago
- Profit per share excluding one-offs: $0.51, down 24% from $0.67 a year ago
While revenue grew 41%, net income fell 30% because research spending nearly doubled, interest expense doubled, and the company booked a $7.0 million tax provision against a $1.3 million tax benefit a year ago. Moreover, patient enrollment for the newly approved heart and lung trials is only now starting, so clinical trial costs will stay elevated across 2027 before kidney devices earn a dollar of commercial sales.
What to watch: the 2027 operating margin outlook on the fourth-quarter call. A target stuck in the low-to-mid teens would confirm that heavy trial and kidney spending prevents a return to the 20% margins seen in the first half of 2025.
Headquarters Lease Doubled Interest Costs
Earlier this year, TransMedics signed a lease for a new headquarters in Somerville, Massachusetts, adding a massive long-term property obligation on top of its convertible notes and bank debt. That real estate commitment now weighs directly on quarterly net income.
Finance lease liabilities on the balance sheet reached $351.5 million at the end of September, lifting total debt and lease obligations by $349.0 million since December to $861.3 million by our math. In addition, the current portion of long-term debt jumped to $54.8 million as bank loan repayments came due within a year, and quarterly interest expense more than doubled from a year ago to $7.3 million.
What to watch: cash on the balance sheet ($493.0 million at quarter-end) and capital spending in the quarterly filing. Paying down the $54.8 million current debt and funding headquarters construction ahead of the 2028 convertible note maturity leaves much less room for cash burn.
Risks this quarter didn't answer
Three standing concerns from last quarter got no new numbers in the earnings release and wait on the quarterly filing or conference call.
- Sales by organ and rival pressure: the release gave no split between liver, heart and lung revenue; the filing's footnote disaggregation will show whether liver held off rival machines and whether US lung sales stopped falling.
- PAD Aviation deal terms: management disclosed $9.4 million of revenue but not the purchase price, ownership stake or profit drag; the acquisition footnote in the filing will show the cash outflow.
- Shareholder lawsuit: the securities class action entered discovery in July and remained only a boilerplate risk line in the release; the legal proceedings footnote will show any status change.
👓 Other Themes
New US Organ Procurement Rule
TransMedics added a new regulatory warning to its forward-looking statements: “the impact of the Centers for Medicare & Medicaid Services final rule on Organ Procurement Organization Conditions for Coverage (CMS-3409-F) released October 30, 2026”. Because US organ procurement groups supply the donor organs that fly on the company's network, how regulators enforce those performance standards could shift donor volume. Separately, the company named former GE HealthCare executive Fernando Araujo as finance chief in September.
💲 Other KPIs
Money owed by hospital customers rose to $114.9 million, up 36.4% from $84.3 million at the end of December 2025 and up from $104.1 million last quarter. Receivables grew slightly faster than the 26.2% rise in quarterly sales over the same nine-month stretch, tying up working capital as transplant volume scaled.
Diluted shares edged up 0.2% from a year ago. Under accounting rules, the nine-month reported diluted count was 36.08 million because the company's convertible notes were anti-dilutive on lower nine-month net income, whereas the nine-month calculation excluding one-offs added 4.89 million shares for those notes.
🔮 Guidance
Raised. The transplant technology group lifted the middle of its underlying full-year outlook by $8 million, pointing to 24% to 26% growth over 2025. By our math, that leaves $197.5 million at the middle of the range for the fourth quarter, or 22.8% growth from a year ago vs 34.6% in the third quarter. It is the second raise this year: unchanged in Q1, +$5M in Q2, +$8M in Q3.
New. Including roughly $14 million from the July investment in PAD Aviation, the company forecasts 26% to 28% total revenue growth for 2026. By our math, after $566.9 million in the first nine months and $9.4 million from PAD in the third quarter, the middle of the range leaves $202.1 million for the fourth quarter (+25.7% from a year ago), including about $4.6 million from PAD.
❓ Key Questions
What were third-quarter revenue and case counts by organ?
Net product revenue accelerated from 15.7% growth in the second quarter to 29.4% in the third, but the release did not split sales between liver, heart and lung. Organ numbers in the quarterly filing will show whether heart grew before the new trial or liver carried the beat.
What did PAD Aviation cost and what is its margin?
TransMedics disclosed $9.4 million in third-quarter charter revenue from PAD Aviation and about $14 million for the full year, but gave no purchase price, ownership percentage or operating expense figure for the German carrier.
Did new CFO Fernando Araujo keep the 12.5%–14% margin outlook?
The earnings release updated only full-year revenue. On last quarter's call, the prior finance chief cut the full-year operating margin outlook excluding one-offs and PAD Aviation to 12.5%–14%; year-to-date margin sits at 12.8% including PAD.
How does the October 30 CMS organ rule affect 2027 volume?
The company added the final rule on Organ Procurement Organization Conditions for Coverage (CMS-3409-F) to its risk factors five days after regulators released it. Investors need to know whether decertification threats will disrupt donor organ supply or push more groups to outsource to TransMedics.